Case Study

IND Amendment Rescue

The Situation

Company: A clinical-stage biopharma company 

Issue: The company was developing an injectable therapy in a standard prefilled syringe and needed support in developing its bridging strategy for an auto-injector.

Projects: 

Project 1: Developing a bridging strategy to an eventual auto-injector configuration

Project 2: Light review support for an upcoming IND amendment

Challenges Expressed:

At project kickoff the sponsor revealed that the IND amendment was only two weeks away from submission, and they required full review of all combination-product–related content.

Once the draft documents were received, it became clear the company faced a deeper issue: They had no device design control documentation, no combination-product QMS structure, and no design history file (DHF). The sponsor’s team believed their CMO maintained the necessary documentation—a common misconception for first-time combination-product developers.

Impact:

  • Initial feedback about these gaps was met with an understandable concern about whether the submission could proceed at all.
  • Minimally, risk of delays and rework that could jeopardize IND timelines.

Discovery:

Our evaluation of documentation, data, design controls, and expected information in a Phase 2 IND amendment for a standard prefilled syringe showed:

  • The components were sourced from well-established platform suppliers
  • The CMO had valid performance and container-closure integrity data
  • No underlying patient-safety risks were present
  • The missing design controls represented a documentation deficiency, not a product-risk deficiency

Solutions Implemented:

  • A structured session explaining Combination-product GMP requirements under 21 CFR Part 4, FDA’s explicit design controls expectations, the long-term risks of proceeding without a device DHF, and options to remediate the compliance gap without delaying essential clinical progress.
  • Edits to the IND amendment, including revised PFS-related Module 3 content, defensible descriptions of testing performed by the CMO, integrated supplier, right-sized the depth of information, and a clear narrative reflecting existing controls and planned future work

     

    The sponsor successfully submitted the IND amendment on schedule despitelacking critical device documentation. They now understand and can implement Part 4 design control expectations, advance the program toward auto-injector development with a clear, compliant roadmap, and build a durable partnership with their device suppliers and CMO.

    For more details on this case study, read our full article.